Evidence map›Paper›PMID 41948347›Full record

ReviewFrontiers in immunology2026

Role play of regulatory T cells and resolvins in type 2 diabetes.

Sandhya Krishnan, Shriraam Mahadevan, Hanuman Prasad Sharma, Undurti Narasimha Das, Kaviarasan Kuppan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sandhya KrishnanDepartment of Biomedical Sciences, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
Shriraam MahadevanDepartment of Endocrinology, Sri Ramachandra Medical College, Chennai, India.
Hanuman Prasad SharmaScientist - II Bioanalytics Facility, Centralized Core Research Facility, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Undurti Narasimha DasUND Life Sciences, Battle Ground, WA, United States.
Kaviarasan KuppanDepartment of Biomedical Sciences, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-grade systemic inflammation is seen in type 2 diabetes mellitus (T2DM), which is also considered the underlying mechanism for the occurrence of major complications observed in these patients. In developing countries like India, prediabetes/insulin resistance is often overlooked. Specialized pro-resolving mediators (SPMs) are a family of anti-inflammatory lipid molecules that are needed to resolve inflammation to maintain immune balance and prevent complications due to DM. Treg cells are a subset of CD4

Indexed as

Diabetes Mellitus, Type 2Specialized Pro-Resolving MediatorsT-Lymphocytes, RegulatoryAnimalsHumansInsulin ResistanceObesitydiabetesinsulin resistancelipid mediatorsobesityresolvinsT regulatory cells (Tregs)

Identifiers

PMID41948347
PMCPMC13050660

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.